Immunai
Comprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
4
Funding Rounds
$313.0m
Money raised
Overview
Comprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
-
Website:
- Business model: B2B
- Social accounts:
| Name | Phone | Social networks | |
|---|---|---|---|
| An Sa* | - | - | - |
| Da* Li | - | - | - |
| Lu** Vo**** |
|
- | |
| No** So |
|
- | |
| Da*** We*** | - | - | - |
Funding
Funding series
Funding Series Analysis
The company Immunai has raised a total of $253m in funding over 4 rounds.
Key Insights:
- Immunai September 2024 Venture - Series Unknown Funding Round: $18m
- Immunai Series B round, October 2021: $215m
- Immunai Seed round, May 2020: $20m
- Immunai Series A round February 2021: $60m
Immunai September 2024 Venture - Series Unknown Funding Round
$18m
Immunai Series B round, October 2021
$215m
Immunai Seed round, May 2020
$20m
Immunai Series A round February 2021
$60m
Industries
Immunai is active in the following industries: